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Sclerostin Antibody Treatment Enhances Rotator
Cuff Tendon-to-Bone Healing in an Animal Model
Shivam A. Shah, PhD, Ioannis Kormpakis, MD, Necat Havlioglu, MD, Michael S. Ominsky, PhD,
Leesa M. Galatz, MD, and Stavros Thomopoulos, PhD
Investigation performed at Washington University in St. Louis, St. Louis, Missouri
Background: Rotator cuff tears are a common source of pain and disability, and poor healing after repair leads to high
retear rates. Bone loss in the humeral head before and after repair has been associated with poor healing. The purpose
of the current study was to mitigate bone loss near the repaired cuff and improve healing outcomes.
Methods: Sclerostin antibody (Scl-Ab) treatment, previously shown to increase bone formation and strength in the
setting of osteoporosis, was used in the current study to address bone loss and enhance rotator cuff healing in an animal
model. Scl-Ab was administered subcutaneously at the time of rotator cuff repair and every 2 weeks until the animals were
sacriﬁced. The effect of Scl-Ab treatment was evaluated after 2, 4, and 8 weeks of healing, using bone morphometric
analysis, biomechanical evaluation, histological analysis, and gene expression outcomes.
Results: Injury and repair led to a reduction in bone mineral density after 2 and 4 weeks of healing in the control and Scl-
Ab treatment groups. After 8 weeks of healing, animals receiving Scl-Ab treatment had 30% greater bone mineral density
than the controls. A decrease in biomechanical properties was observed in both groups after 4 weeks of healing compared
with healthy tendon-to-bone attachments. After 8 weeks of healing, Scl-Ab-treated animals had improved strength (38%)
and stiffness (43%) compared with control animals. Histological assessment showed that Scl-Ab promoted better inte-
gration of tendon and bone by 8 weeks of healing. Scl-Ab had signiﬁcant effects on gene expression in bone, indicative
of enhanced bone formation, and no effect on the expression of genes in tendon.
Conclusions: This study provides evidence that Scl-Ab treatment improves tendon-to-bone healing at the rotator cuff
by increasing attachment-site bone mineral density, leading to improved biomechanical properties.
Clinical Relevance: Scl-Ab treatment may improve outcomes after rotator cuff repair.
R
otator cuff tears do not heal spontaneously, can prog-
ress in size over time, and motivate >250,000 surgical
repairs in the United States annually1. Poor tendon-to-
bone healing after repair results in an alarmingly high rate of
retears at the site of attachment, ranging from 20% in young
healthy patients with small tears to 94% in older patients with
massive tears2,3. Rotator cuff tears are associated with loss of
bone at the healing interface and a lack of regeneration of
the functionally graded, mineralized ﬁbrocartilage found in the
healthy attachment4. Bone loss has been observed at healing
tendon-to-bone interfaces at multiple anatomic sites5-11. The
loss of mineralized tissue is likely caused by mechanical un-
loading during the period from tearing through surgical repair
and by high osteoclast activity during the healing period after
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repair10,12. Chronic rotator cuff tears lead to unloading-induced
osseous changes to the humeral head13. Chronic degeneration of
the muscle before repair is associated with greater bone loss in
the humeral head and leads to low cellular remodeling and poor
extracellular matrix formation14. However, Ditsios et al. showed
that mechanical unloading is not the only factor accountable for
the reduction in bone mineral density (BMD) at the healing
tendon-to-bone attachment15. Injury to the ﬂexor digitorum
profundus tendon in an animal model without any alteration of
limb loading resulted in a sevenfold increase in osteoclast surface
after 7 days, leading to a 7% decrease in BMD after 21 days.
To address the bone loss that occurs during tendon-to-
bone healing, investigators in a previous study suppressed osteo-
clast activity using bisphosphonate treatment8,9,16. Treatment led
to improved mechanical properties in the treatment group
compared with the control group. However, therapy with bis-
phosphonates is not ideal, especially in the younger population,
because of its association with reduced bone turnover and in-
creased risk for bone fracture17-19. Another approach to increase
bone mass at the site of healing is to administer a bone-anabolic
agent to stimulate new bone formation. Sclerostin antibodies that
block sclerostin, a negative regulator of bone formation produced
largely by osteocytes, systemically increase bone formation and
bone mass in animal models and osteoporotic patients20-22. In the
current study, a novel application of sclerostin antibody (Scl-Ab)
treatment was tested for enhancing tendon-to-bone healing. Us-
ing a well-established animal model of the rotator cuff, we tested
the hypothesis that Scl-Ab treatment would prevent bone loss
during tendon-to-bone healing, leading to improved outcomes.
Materials and Methods
Animal Model and Study Design
Eighty-seven adult male Sprague-Dawley rats (approximately 4months old andweighing approximately 350 g) were used in this study, as approved by the
Institutional Animal Care and Use Committee. Fifty-three rats received surgical
injury and repair, and 34 rats were used as uninjured controls (the normal group).
Of the 53 injured-and-repaired rats, 10 (5 that received Scl-Ab [the Scl-Ab group]
and 5 that had no treatment [the control (CTL) group]) were used to study 2weeks
of healing, 20 (10 in the Scl-Ab treatment group and 10 in the CTL group) were
used to study 4 weeks of healing, and 23 (12 in the Scl-Ab treatment group and 11
in the CTL group) were used to study 8 weeks of healing. Of the 34 uninjured
control animals, 17 were used to study the effect of Scl-Ab treatment on the healthy
rotator cuff and 17 were used as healthy untreated controls. For all animals,
1 shoulder was used for bone morphometry and/or biomechanical evaluation and
the contralateral shoulder was used for histological analysis or gene expression.
For rats in the injury-and-repair groups, the supraspinatus tendon was
sharply severed from the humeral head and was repaired bilaterally in each
animal, as previously described
23
. Operatively and nonoperatively treated an-
imals either were left untreated (the CTL group) or were administered Scl-Ab
(Scl-Ab VI; Amgen). The Scl-Ab was delivered via subcutaneous injections
(25 mg/kg) at the onset of the study (i.e., at the time of injury and repair for the
operatively treated animals and at an equivalent age for the nonoperatively
treated animals) and every 2 weeks until they were killed (the Scl-Ab group).
Animals in the operatively treated CTL and Scl-Ab groups were allowed cage
activity and were sacriﬁced after 2, 4, or 8 weeks. Animals in the nonoperatively
treated CTL and Scl-Ab groups were allowed cage activity and were sacriﬁced
after 4 weeks. Postmortem supraspinatus muscle-tendon-bone samples were
dissected and assessed using bone morphometry, biomechanical evaluation,
histological analysis, and gene expression. As surgery was performed bilaterally
and the treatment was systemic, each animal had 2 samples available for
analysis. Samples were allocated to either bone morphometry followed by
biomechanical evaluation or bonemorphometry followed by either histological
analysis or gene expression.
At the time that the animals were killed, body weight was not signiﬁ-
cantly different between treatment groups (mean [and standard deviation]
across time points, 520 ± 54 g for Scl-Ab group and 510 ± 55 g for the CTL
group). No repair site failure or gap was observed in the Scl-Ab and CTL groups
at the time of dissection.
Bone Morphometric Analysis
After the animals were sacriﬁced, the humerus with the supraspinatus tendon
and muscle attached was dissected for bone morphometric analysis (17 per
group of nonoperatively treated rats, 5 per group of operatively treated rats after
2 weeks of healing, and 20 to 23 per group of operatively treated rats after
4 or 8 weeks of healing). The humeral head and tendon enthesis region
TABLE I The Modiﬁed Tendon-to-Bone Maturity Score with Evaluation of 9 Individual Outcomes on a Scale of 1 to 4*
Score
Individual Outcomes 1 2 3 4
Cellularity (inﬂammation) Minimal Mild Moderate Marked
Presence of ﬁbrocytes (%) >75 51-75 26-50 £25
Proportion of cells oriented
parallel (%)
>75 51-75 26-50 £25
Proportion of ﬁbers oriented
parallel (%)
>75 51-75 26-50 £25
Presence of matrix Marked Moderate Mild Minimal
Insertion integrity C(1), R(1), F(1), tidemark(1) C(1), R(1), F(1), tidemark(2) C(1), R(1), F(2) C(1), R(2)
Insertion continuity (%) >75 51-75 26-50 <25
Bone resorption at enthesis (%) £25 26-50 51-75 >75
Epiphyseal bone modeling (%) £25 26-50 51-75 >75
*Modiﬁcation of the system of Ide et al.25. A healthy (uninjured) enthesis has a combined score of 9. C = continuity, R = regularity, and F = ﬁbrocartilage.
856
THE JOURNAL OF BONE & JOINT SURGERY d J B J S .ORG
VOLUME 99-A d NUMBER 10 d MAY 17, 2017
SCLEROST IN ANTIBODY ENHANCES ROTATOR CUFF TENDON-TO-
BONE HEAL ING IN AN ANIMAL MODEL
(approximately 5 mm) were scanned using micro-computed tomography
(microCT) at a resolution of 20 mm, 45 kVp, and 177 mA (mCT 40; SCANCO
Medical)
13,24
. The region of interest included trabecular bone within the hu-
meral head near the tendon attachment (within approximately 1 mm) and
proximal to the growth plate and was determined by evaluators blinded to the
treatment groups. The amount of bone in the region of interest was calculated
to determine bone volume fraction (BV/TV; bone volume to total volume).
BMD, trabecular number (Tb.N), trabecular thickness (Tb.Th), and tra-
becular spacing (Tb.Sp) were also determined.
Biomechanical Evaluation
After killing, dissection, and microCTscanning of the animals, the supraspinatus
tendon-to-bone attachment was mechanically tested in uniaxial tension (17 per
group for nonoperatively treated animals and 10 to 12 per group for operatively
treated animals)
13
. The repair-site suture was released to remove its mechanical
contribution, the humeri were potted in polymethylmethacrylate, and specimens
were tested in a 0.9% saline solution water bath at 37C (Instron 5866). Samples
were preconditioned for 5 cycles (5% strain, 0.2%/s), allowed 300 seconds for
recovery, and pulled to failure at 0.2%/s. Strain was determined from grip-to-grip
displacement. Cross-sectional area near the attachment site was measured from
microCT scans by evaluators blinded to treatment group. Load-deformation
curves were used to determine maximum load and stiffness. Stress-strain curves
were used to determine strength (maximum stress), modulus, and resilience (area
under the curve from 0% to yield strain). The mechanism of failure was deter-
mined visually. Specimens were excluded from the data analysis if the tendon
slipped out of the grip or failure occurred at the growth plate of the humeral head.
Histological Analysis
Histological analysis was performed for the CTL and Scl-Ab-treated groups
following 2, 4, and 8 weeks of healing (3 animals per group). Humerus-
supraspinatus constructs were ﬁxed in 4% paraformaldehyde for 24 hours.
Samples were decalciﬁed in 14% EDTA (ethylenediaminetetraacetic acid), de-
hydrated in graded ethanol, and embedded in parafﬁn. Five-micrometer cor-
onal sections were stained with hematoxylin and eosin, toluidine blue, or
Goldner trichrome. Additional samples were ﬁxed for 24 hours in 4% para-
formaldehyde and embedded in plastic, and 5mm-thick coronal sections were
stained with von Kossa stain. The sections were semiquantitatively analyzed by
1 blinded observer (N.H.) using a tendon-to-bone maturity score adapted from
Ide et al.
24,25
. Insertion continuity, bone resorption, matrix quality, cell and
ﬁber alignment, and cellularity were part of 9 factors evaluated on a scale from
TABLE II Names of Genes, Associated Categories, and TaqMan Assay Identiﬁcation Numbers*
Gene Name Category TaqMan Assay ID
Tnfrsf11b (tumor necrosis factor receptor superfamily,
member 11b), OPG (osteoprotegerin)
Bone, inhibits osteoclast activity Rn00563499_m1
Sost (sclerostin) Bone, osteoclast activity Rn00577971_m1
Dmp1 (dentin matrix acidic phosphoprotein) Bone, osteoclast activity Rn01450122_m1
RankL (receptor activator of nuclear factor kappa-B ligand),
Tnfsf11 (tumor necrosis factor [ligand] superfamily, member 11)
Bone, osteoblast activity Rn00589289_m1
Bglap (bone gamma-carboxyglutamate protein), OCN (osteocalcin) Bone, osteoblast activity Rn00566386_g1
Pth1r (parathyroid hormone 1 receptor) Bone, osteoblast activity Rn00571596_m1
Ctsk (cathepsin K) Bone, bone resorption Rn00580723_m1
Dkk1 (dickkopf WNT signaling pathway inhibitor 1) Bone, Wnt signaling antagonist Rn01501537_m1
Lrp5 (low density lipoprotein receptor-related protein 5) Bone, Wnt signaling Rn01451428_m1
Runx2 (runt-related transcription factor 2) Bone, osteoprogenitor Rn01512298_m1
Sp7 (Osterix) Bone, osteoprogenitor Rn02769744_s1
Scx (scleraxis) Tendon Rn01504576_m1
Tnmd (tenomodulin) Tendon Rn00574164_m1
Col1a1 (collagen, type I, alpha 1) Tendon Rn01463848_m1
Col1a2 (collagen, type I, alpha 2) Tendon Rn01526721_m1
Col3a1 (collagen, type III, alpha 1) Tendon Rn01437681_m1
Col2a1 (collagen, type II, alpha 1) Fibrocartilage Rn01637087_m1
Acan (aggrecan) Fibrocartilage Rn00573424_m1
Tgfb1 (transforming growth factor, beta 1) Fibrocartilage Rn00572010_m1
Tgfb3 (transforming growth factor, beta 3) Fibrocartilage Rn00565937_m1
Mmp2 (matrix metalloproteinase 2) Fibrocartilage Rn01538170_m1
Sox9 (SRY [sex determining region Y]-box 9) Fibrocartilage Rn01751069_mH
Smo (smoothened, frizzled class receptor) Development Rn00563043_m1
Notch1 Development Rn01758633_m1
Rpl13a (ribosomal protein L13A) Housekeeping Rn00821946_g1
*TaqMan Gene Expression Assays are manufactured by ThermoFisher Scientiﬁc.
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Fig. 1
Treatment with Scl-Ab increased bone volume fraction (BV/TV) (Fig. 1-A), bonemineral density (BMD) (Fig. 1-B), trabecular number (Tb.N) (Fig. 1-C),
and/or trabecular thickness (TbTh) (Fig. 1-D) in the normal (uninjured) and 8-week healing groups. A signiﬁcant effect of Scl-Ab is indicated
by a line over bars (p < 0.05; ANOVA followed by Tukey post hoc test compared with CTL within group). A signiﬁcant difference compared with
normal is indicated by an “a” within a bar (p < 0.05; ANOVA followed by the Tukey post hoc test compared with normal within a particular treatment
group). CTL = control.
Fig. 2
Treatment with Scl-Ab led to increased attachment-site failure load (Fig. 2-A), strength (Fig. 2-B), and stiffness (Fig. 2-C) after 8 weeks of healing,
and stiffness and modulus (Fig. 2-D) were decreased in normal (uninjured) attachments. A signiﬁcant effect of Scl-Ab is indicated by a line over bars
(p < 0.05; ANOVA followed by Tukey post hoc test compared with CTL within group). A signiﬁcant difference compared with normal is indicated by an
“a” within a bar (p < 0.05; ANOVA followed by the Tukey post hoc test compared with normal within a particular treatment group). CTL = control.
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1 to 4 (Table I). A lower score is indicative of improved tendon-to-bone healing,




For gene expression studies (4 per group), humerus-supraspinatus samples
were frozen in liquid nitrogen. RNA was isolated separately from the supra-
spinatus tendon and the portion of the humeral head proximal to the growth
plate near the tendon attachment (RNeasy Kit; Qiagen). RNA was quantiﬁed
using a NanoDrop 2000 (ThermoFisher Scientiﬁc). Quantitative real-time
polymerase chain reaction (PCR) was performed using a Biomark HD System
(Fluidigm) for tendon and bone RNA on a panel of 25 genes related to bone,
tendon, and ﬁbrocartilage (Table II). TaqMan gene expression assays
(ThermoFisher Scientiﬁc) were used for the analysis. Rpl13a was used as
a housekeeping gene, as expression of Rpl13a did not vary more than ±0.5 Ct
Fig. 3
Photomicrographs made after 8 weeks of healing show that Scl-Ab treatment (Figs. 3-B and 3-D) improved insertion continuity, integrity, and ﬁber
alignment compared with CTL (Figs. 3-A and 3-C). The enthesis area is outlined with a white dashed box. Scale bars = 1 mm for Figs. 3-A and 3-B and
250 mm for Figs. 3-C and 3-D. Slides were stained with Masson trichrome.
TABLE III The Modiﬁed Tendon-to-Bone Maturity Scores*
2 Weeks 4 Weeks 8 Weeks
CTL Scl-Ab CTL Scl-Ab CTL Scl-Ab
Cellularity 2 (1, 3) 3 (2, 3) 1 (1, 1) 1 (1, 2) 1 (1, 1) 1 (1, 1)
Fibroblasts 2 (1, 2) 2 (2, 2) 1 (1, 1) 1.5 (1.5, 2) 1 (1, 2) 1 (1, 1)
Matrix 4 (1, 4) 2 (2, 3) 3 (2.5, 3) 2.5 (1, 3) 2 (2, 3) 1.5 (1, 2.5)
Cell orientation 3 (1, 3) 2 (2, 3) 2 (2, 3) 1.5 (1, 3) 2 (1, 2) 1 (1, 1)
Collagen orientation 3 (1, 3) 2 (2, 3) 2 (2, 3) 1.5 (1, 3) 2 (1, 2) 1 (1, 1)
Insertion integrity 3 (1, 4) 1.5 (1.5, 2) 2.5 (2.5, 3) 2.5 (1, 2.5) 2.5 (1.5, 3) 1.5 (1, 2.5)
Insertion continuity 3 (1, 4) 2 (2, 3) 3 (3, 3) 3 (1, 3) 2 (1, 3) 1 (1, 2)
Bone resorption 3 (2, 4) 4 (3, 4) 3 (2, 4) 3 (3, 4) 3 (3, 4) 4 (4, 4)
Epiphyseal bone
modeling
3 (1, 4) 4 (3, 4) 4 (3, 4) 4 (3, 4) 4 (4, 4) 4 (4, 4)
Overall maturity 24 (14, 29) 22.5 (22, 23.5) 21 (19.5, 25) 20.5 (15.5, 24.5) 21.5 (16.5, 22) 16 (15, 19)
*The results are shown as the median (minimum, maximum). The modiﬁed tendon-to-bone maturity scores improved over time for all groups.
Scl-Ab treatment resulted in a more mature attachment at 8 weeks of healing compared with CTL.
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Fig. 4
Gene expression in mineralized tissue adjacent to the tendon enthesis relative to the housekeeping gene Rpl13a. A signiﬁcant effect of Scl-Ab is indicated
by a line over bars (p < 0.05; ANOVA followed by Tukey post hoc test compared with CTL within group). A signiﬁcant difference compared with normal
is indicated by an “a” within a bar (p < 0.05; ANOVA followed by Tukey post hoc test compared with normal within a particular treatment group).
A signiﬁcant effect of Scl-Ab compared with normal in the CTL group is indicated by a “b” within a bar (p < 0.05; ANOVA followed by the Tukey post hoc
test). CTL = control, Pth1r = parathyroid hormone 1 receptor, and Ctsk = cathepsin K.
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(cycle threshold value) among groups. Results are presented as relative expression
compared with Rpl13a expression (2-DCt).
Statistical Analysis
The primary outcome tested in this study was the effect of Scl-Ab treatment.
To incorporate the effect of healing duration, a 2-factor analysis of variance
(ANOVA), in which the factors analyzed were Scl-Ab treatment and healing
time, was performed. When the ANOVAwas signiﬁcant, Tukey post hoc tests
were performed to determine speciﬁc effects of treatment (CTL or Scl-Ab)
and duration of healing (2, 4, or 8 weeks). A secondary outcome tested in
this study was the effect of injury and repair. Comparisons between the
uninjured control group (the normal group) and the injury-and-repair
groups (CTL or Scl-Ab group) were performed using 2-tailed Student t tests.
A p value of <0.05 was considered signiﬁcant for all comparisons. SYSTAT
13 software (Systat Software) was used for all statistical analyses. Error bars
in the plotted data represent 1 standard deviation from the mean. Due to the
semiquantitative nature of the histological analysis and the low sample size




There was signiﬁcant bone loss in the CTL and Scl-Abgroups by 4 weeks of healing, with recovery in the Scl-Ab
group by 8 weeks of healing (Fig. 1). Speciﬁcally, BV/TV, BMD,
and Tb.N in the CTL group and BMD in the Scl-Ab group were
signiﬁcantly decreased compared with the uninjured group at
4 weeks. However, after 8 weeks of healing, in the Scl-Ab treatment
group compared with the CTL group, the BV/TV was increased
by 34%, BMD was increased by 30%, Tb.N was increased by
17%, Tb.Th was increased by 24%, and TbSp was decreased by
21% (Fig. 1; see Appendix), reaching levels comparable with
those of the uninjured control group. Treatment with Scl-Ab also
led to increased BV/TV, BMD, and Tb.Th in the uninjured groups
as well. When evaluating the overall effect of Scl-Ab treatment
using an ANOVA, Scl-Ab-treated animals had signiﬁcantly higher
BV/TV, BMD, and Tb.Th compared with CTL animals, by 19%,
18%, and 20%, respectively.
Biomechanical Evaluation
Eleven of 77 samples were excluded from analysis be-
cause they did not fail at the tendon attachment; the ex-
cluded samples included 4 operatively treated shoulders from
the Scl-Ab group and 4 from the CTL group and 2 non-
operatively treated shoulders from the Scl-Ab group and
1 from the CTL group. Injury caused a signiﬁcant increase in
cross-sectional area (mean and standard deviation, 15.9 ±
3.9 mm2 compared with 6.6 ± 1.9 mm2). There was a sig-
niﬁcant decrease in mechanical properties in the CTL and
Scl-Ab groups by 4 weeks of healing, with improved me-
chanical properties in the Scl-Ab group by 8 weeks of healing
(Fig. 2; see Appendix). After 8 weeks of healing, comparison
of the Scl-Ab treatment and CTL groups demonstrated that
failure load was increased by 48%, strength was increased by
Fig. 5
Gene expression in the tendon relative to the housekeeping gene Rpl13a. A signiﬁcant difference compared with normal is indicated by an “a” within
a bar (p < 0.05; ANOVA followed by the Tukey post hoc test compared with normal within a particular treatment group).
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38%, and stiffness was increased by 43%. Treatment with
Scl-Ab also led to signiﬁcant decreases in stiffness and mod-
ulus in the uninjured groups.
Histological Analysis
Supraspinatus tendon healing to humeral head bone occurred
via a ﬁbrovascular scar, with bone loss evident in the humeral
heads of the CTL group (Fig. 3). Based on a blinded analysis of 9
features of the healing tendon-to-bone attachment, the CTL and
Scl-Ab healing attachments appeared similar at 2 and 4 weeks of
healing (Table III). However, after 8 weeks of healing, the Scl-Ab
treatment led to improved insertion continuity, integrity, and
ﬁber alignment compared with the CTL group. The analysis
demonstrated a more mature tendon-to-bone attachment and
new bone formation in the Scl-Ab group compared with CTL
group at 8 weeks (Table III).
Gene Expression
Mineralized Tissues (Bone and Fibrocartilage)
The Scl-Ab treatment had a signiﬁcant effect on the expression
of a number of genes in mineralized tissue near the tendon
enthesis, including Sclerostin, Dkk1 (dickkoph-related protein 1),
RankL (receptor activator of nuclear factor kappa-B ligand),
Dmp1 (dentin matrix acidic phosphoprotein 1), and Runx2
(runt-related transcription factor-2) (Fig. 4). After 8 weeks of
healing, expression of Sclerostin and Dkk1 was 3.3 times and
2.5 times greater in the Scl-Ab group compared with the CTL
group, respectively. Expression of Lrp5 (low-density lipopro-
tein receptor-related protein 5) was not affected by treatment
or healing time. Osteocalcin (Ocn), a marker of osteoblast
activity, was signiﬁcantly increased following injury, while os-
teoprotegerin (Opg), a marker of osteoclast inhibition, was
signiﬁcantly decreased after injury in all groups. Expression of
RankL and Dmp1 was increased with Scl-Ab treatment (Fig. 4;
see Appendix). There was no consistent effect of Scl-Ab
treatment on the ﬁbrocartilage-related genes Tgf (trans-
forming growth factor)-b1, Tgf-b3, Mmp (matrix metal-
loproteinase 2), Col2a1 (collagen type II alpha 1), and Sox9
(Fig. 4; see Appendix). Expression of Smo and Notch1,
members of the hedgehog signaling pathway, was not affected
by treatment.
Tendon Gene Expression
Scl-Ab treatment had no signiﬁcant effect on tendon gene
expression (Fig. 5; see Appendix). Healing time, however,
signiﬁcantly affected all tendon-related genes: Scleraxis,
Tenomodulin, Col1a1 (collagen type I alpha 1), Col1a2
(collagen type I alpha 2), and Col3a1 (collagen type III alpha 1).
Changes were most apparent at the 2-week healing time point
and trended toward normal by the 8-week healing time point.
Additionally, expression of aggrecan was 20 times greater in the
CTL group and 17 times greater with Scl-Ab treatment after
2 weeks of healing. Similarly, expression of Mmp2 was 4.1 times
greater in both the CTL and Scl-Ab treatment groups after
2 weeks of healing.
Discussion
Rotator cuff injury and repair led to bone loss at the tendon-to-bone interface. A decrease in bone quantity and quality
at the healing interface contributes to the high rates of retear
following surgical repair3. Scl-Ab treatment increased bone
volume fraction and BMD of the trabecular bone in the humeral
head nearest to the healing tendon attachment. Although injury-
associated bone loss remained in the treatment group after
8 weeks of healing, rapid recovery toward normal bone was seen
by 8 weeks of healing in the treated animals. The improvement
in bone morphology at the healing interface had functional con-
sequences, as demonstrated by improved attachment strength.
Qualitative histological assessment further conﬁrmed the beneﬁt
of Scl-Ab treatment, with a more mature tendon-to-bone in-
terface after 8 weeks of healing in the treated animals compared
with control animals.
Delivery of osteoinductive agents such as bone mor-
phogenetic protein-2 to repaired tendon-to-bone attachments
has been ineffective in improving healing24,26. However, bis-
phosphonates have previously shown success in improving
tendon-to-bone healing by reducing bone resorption16,27. In a
canine model of ﬂexor tendon-to-bone healing, tendon injury
caused BMD near the tendon-to-bone interface to decrease
by 29% compared with normal after 21 days16. An oral dose of
alendronate was effective in preventing bone resorption,
leading to only a 6% decrease in BMD compared with normal.
The prevention of bone loss resulted in a signiﬁcant improve-
ment in the failure load of the repair after 21 days of healing. In
a separate study, subcutaneous injections of zoledronic acid to
ovariectomized rats resulted in a 23% increase in BMD of the
humeral head near the supraspinatus tendon insertion com-
pared with the control27. The increased BMD was associated
with a 24% increase in failure load at the interface following
treatment. In the current study, after 8 weeks of healing, Scl-Ab
treatment caused a 30% increase in BMD and a 48% increase in
failure load compared with the control, consistent with the
prior bisphosphonate treatment approaches.
The Scl-Ab used in the current study has been previously
shown to neutralize sclerostin by preventing sclerostin binding
to the Lrp5 receptor28-30. To determine whether improvements
in bone morphology during tendon-to-bone healing were
achieved through this mechanism, we measured expression of
Wnt signaling-related genes in the mineralized tissues at the
healing attachment. Scl-Ab treatment increased expression of
the Wnt-target genes sclerostin and Dkk1 relative to control
during tendon-to-bone-healing, in contrast to decreases ob-
served in controls relative to normal, uninjured attachments.
The changes observed in the Scl-Ab group indicate a com-
pensatory cellular response to chronic use of Scl-Ab treatment,
as described by Taylor et al.31. Further analysis of bone-related
gene expression showed a reduction of osteoclast inhibition (as
demonstrated by an increase in Opg relative to RankL) and an
increase in osteoblast activity (as demonstrated by increased
osteocalcin) with Scl-Ab, consistent with the observed im-
provements in bone morphology. Genes related to osteopro-
genitors (Osterix and Runx2) were signiﬁcantly increased with
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injury compared with normal, uninjured groups. These genes,
however, were not affected by treatment in healing bone,
although Runx2 was increased by Scl-Ab in normal, uninjured
bone. Increased expression of these factors, which are also as-
sociated with differentiation of mesenchymal cells into osteo-
blasts32,33, suggests the possible induction of bone formation
via progenitors as well as mature osteoblasts.
The strength of the tendon attachment is in large part dic-
tated by the quality of the mineralized tissue at the interface34,35.
The healthy tendon-to-bone attachment has a gradient of mineral
content across the ﬁbrocartilaginous insertion and into the tra-
becular bone36. The increase in mechanical strength at the attach-
ment because of Scl-Ab treatment is likely the result of improved
mineralization in not only the trabecular bone compartment (as
measured by microCT) but also the ﬁbrocartilage at the healing
interface. Expression of aggrecan, an extracellular matrix marker
of cartilage and ﬁbrocartilage, was signiﬁcantly higher with Scl-Ab
treatment after 8weeks of healing. Furthermore, blinded evaluation
of histological sections showed improvements in tendon-to-bone
attachment maturity, including insertion integrity, after 4 and 8
weeks of healing with Scl-Ab treatment compared with controls.
Scl-Ab was administered by subcutaneous injection; there-
fore, all tissues were exposed to the antibody, including the tendon
adjacent to the healing interface. To evaluate possible effects of Scl-
Ab on nonmineralized tissues, gene expression was examined in
the supraspinatus tendon adjacent to the healing interface. Scl-Ab
treatment did not have a signiﬁcant effect on expression of genes in
tendon tissue, alleviating the concern of possible effects of treat-
ment on off-target tissue. However, Scl-Ab treatment did lead to
a decrease in modulus and stiffness in healthy tendon-to-bone
attachments. This result is consistent with a previous ﬁnding
that bisphosphonate treatment during tendon-to-bone healing can
cause a decrease in stiffness16. Due to the high mechanical safety
factor of tendons and ligaments for typical physiologic activities37,
the relatively small decreases in stiffness and modulus may not
predispose healthy tendons to injury. However, possible conse-
quences of the reduced stiffness and modulus at uninjured at-
tachments should be further considered.
There were several limitations to the current study. The
animal model consisted of an acute injury and repair. In con-
trast, most rotator cuff tears in the clinical population occur
after chronic tendon degeneration. Bone loss in these cases may
therefore be more severe than in the current animal study. It is
unclear whether Scl-Ab treatment would be effective in the
chronic injury scenario, although studies have shown efﬁcacy
of the treatment approach in the context of osteoporosis20-22.
Additional animal and clinical studies are necessary to test this
premise. A second limitation of this study was the use of sub-
cutaneous (i.e., systemic) high-dose injections of Scl-Ab. This
dosing regimen (25 mg/kg every 2 weeks) has been reported in
proof-of-concept studies across various animal models38-40,
although future studies would be required to determine the dose-
response to Scl-Ab for tendon-to-bone healing and potential ap-
plication of Scl-Ab via local delivery. Finally, an additional control
group consisting of vehicle injection would have strengthened the
study design. In the current study, treatment was compared with
the equivalent of “standard of care,” i.e., repair only without ad-
ditional biologic treatment.
In conclusion, bone loss was observed at the healing
tendon-to-bone interface, contributing to poor outcomes.
Treatmentwith Scl-Ab improvedhealing by increasing attachment-
site BMD, leading to improved biomechanical properties.
Considering recent evidence that Scl-Ab (i.e., romosozumab,
for human use) is safe and effective for treating osteoporosis in
humans20,41, the results from the current study support the use
of the treatment in combination with repair of acute rotator
cuff tears. Treatment is expected to enhance tendon-to-bone
repair, by improving bone morphology and tendon insertion
maturity, leading to improved tendon attachment strength.
Appendix
Figures demonstrating the effect of treatment with Scl-Ab
and 8 weeks of healing on trabecular spacing and resil-
ience, gene expression in mineralized tissue adjacent to the
tendon enthesis, and gene expression in the tendon are avail-
able with the online version of this article as a data supplement
at jbjs.org (http://links.lww.com/JBJS/D273). n
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